The first breakthrough drug in 30 years for people living with sickle cell disease has been announced by drugs firm Novartis.
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent crises attacks for use in Europe.
These attacks disrupt patients’ lives physically, socially, and emotionally, and can increase risk of organ damage and early death.
Clinical data showed that use of Adakveo led to a significant reduction in their rate, and to fewer days spent in hospital.
SUBSCRIBE to our YouTube channel for more videos: www.youtube.com/skynews
Follow us on Twitter: twitter.com/skynews
Like us on Facebook: www.facebook.com/skynews
Follow us on Instagram: www.instagram.com/skynews
For more content go to news.sky.com and download our apps:
Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí www.youtube.com/channel/UCzG5BnqHO8oNlrPDW9CYJog